Smit Giri MD MHS

@drjgauthier @RahulBanerjeeMD @End_myeloma 2/2. Therefore model building, calibration, external validation & estimation of optimism less relevant. One could make argument for DCA, that too would be better suited for model primarily intended for accurately predicting an outcome IMO.

@drjgauthier @RahulBanerjeeMD @End_myeloma 1/2 Sorry for late reply, was taking a break from X. don't disagree with above general statements. Intent was comparison of predictive discrimination of two thresholds (as in Begg et al PMID: 10900448), conditional on established measures. Outcome prediction accuracy not intended

As usual, masterfully written (no pun intended) by @End_myeloma @smith__giri et al. #MMsm sMRD- at 10^-5 performed better than sMRD- at 10^-6. Turned many heads at #ASH24. May be small n, or: 👇🏼 Maybe sMRD ≤10^-5 catches the most pts and gives us the prognostic info we need!

Underutilization of guideline‐rec supportive care among older adults w/ myeloma in US [Aug 5, 2019] @smith__giri et al @JournalCancer ow.ly/s3Kb30pl8yw #mmsm #SuppOnc #IDonc #geriheme #cancerdisparities lower odds of influenza vaccination in 1st yr of Dx if Black & Medicaid

@davidevelasqu @elplanetaboston Such an inspiring story. Congratulations and best wishes for your future

This is my dad. He was shot twice fighting for democracy in his home country, Nicaragua. He lost his brother in battle. His calloused hands remind me of the manual labor he worked to make sure I could focus on school. He transports elderly patients to their doctors' appointments. He is a warrior. You kept us strong, dad. 2/4

This is my mom. She was an asylum seeker. She slept in a church b/c she had nowhere else to go. She is a housekeeper & a waitress. She is my hero. These degrees are for her. Harvard Medical School, M.D. ✅ Harvard Business School, M.B.A. ✅ Harvard Kennedy School of Government, M.P.P. ✅ You made history happen, mom. 1/4

@Ashley_Rosko1 Very nice work. Congratulations

5. And what does that mean? Exploring objective blood based markers to gauge physiologic health can help clinicians better design treatment NOT on chronologic age. That is a good thing to right-size cancer treatment.

So happy to share our work on biomarkers of aging in Hematologic malignancy. Some important take homes on translational geroscience! A 🧵 #Gerionc @ChristinBurd pubmed.ncbi.nlm.nih.gov/38678524/

@AnnetteHay1 @tanyawildes @HiraSMian @CDNCancerTrials Congratulations @HiraSMian

Congratulations to @HiraSMian Hugely deserving recipient of the @CDNCancerTrials Ralph Meyer New Investigator Award #woMMen

Geriatric assessment-identified impairments and frailty in adults with cancer younger than 65: An opportunity to optimize oncology care geriatriconcology.net/article/S1879-… @mpergolottiPhD @smith__giri @GrantWilliamsMD @WilliamDale_MD @rochgerionc @myCARG #GeriOnc #OlderAdults #OncoAlert

@IshwariaMD @ASCO Many congratulations and well deserved @IshwariaMD

🔸#FASCO! Grateful to @ASCO for giving volunteers like me such meaningful opportunities to come together and give back to #oncology while forming our own incredible community of colleagues who’ve become collaborators and friends from across the country and world!🔸Congrats to my remarkable colleagues and #FASCO honorees this quarter, @GillSharlene @TGeorgeMD @PamelaKunzMD @DrPhilKantoff @DrRanaMcKay @JeamesSailor @shail_maingi and @EdgardoSantosMD! 🔸Can’t wait for #ASCO24!

Racial differences in body composition and survival among older adults with gastrointestinal malignancies #secst0030" target="_blank" rel="nofollow noopener">geriatriconcology.net/article/S1879-… @MFowlerPhD @smith__giri @GrantWilliamsMD @WilliamDale_MD @rochgerionc @myCARG #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #RacialDisparities

T cell exhaustion markers in multiple myeloma patients before and after physical activity intervention - Joseph et al. #ASCO23 Abstract 8060 meetings.asco.org/abstracts-pres… #mmsm #ImmunoOnc HT @rahulbanerjeeMD

@SuyogCancer @ASCO @OncoAlert @DrChoueiri @tompowles1 @montypal @dr_yakupergun @DrYukselUrun To help find the answer the question will need to be properly reframed: why did pembrolizumab show a signal of efficacy whereas nivolumab was inconclusive? See section 10 “Comparative and Group-specific inferences” here for the tools needed 👇

💯 Real world evidence is marketing terminology for the old “observational evidence” and implies that somehow RCTs don’t happen in the “real world”. Complete BS

@BrilazaShop Mr cr try

This Periodic Table Display embeds actual samples of 83 of the 118 elements, including pure bubbles of the gaseous elements. 🔥 Get it Now! 👉 Brilaza.com/periodic-table…

@BrilazaShop Isn’t m this looks to m

Effect of home-based resistance training on chemotherapy relative dose intensity and tolerability in colon #cancer: The FORCE randomized control trial. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… @ACS_Research @JournalCancer @DanaFarber #ExerciseOncology #CancerResearch #SuppOnc

@DavidSteensma I

Stumbled across a fascinating case report. John Hughes Bennett (1812-1875) described Aspergillus; he's known among h(a)ematologists for publishing a clear description of leuk(a)emia in 1845, as did Rudolf Virchow. But a tragic case report is also part of his legacy./1 #MedTwitter

@DavidSteensma I’m k sorry 😣 but but it’s ok ✅ thank o

@rajshekharucms @EliasKarlMai @ManniMD1 @arjunlakshmanMD @SusanBal9 @MeeraMohanMD @AaronGoodman33 @MalinHultcrantz @Amyloid_Planet Mayo 2/20/20 paper defined progression loosely (28% wo CRAB) IMWG paper unclear to me. True CRAB progression likely lower even in those papers. IMO,problem with SMM models is poor Calibration, essential to drive rx decisions, regardless of discrimination. @End_myeloma @SusanBal9

Curious to hear thoughts from SMM aficionados @EliasKarlMai @ManniMD1 @arjunlakshmanMD @SusanBal9 @MeeraMohanMD @AaronGoodman33 @MalinHultcrantz @Amyloid_Planet

Imp. paper by @VincentRK 𝑒𝑡 𝑎𝑙 on mode of progression in a 𝐦𝐨𝐝𝐞𝐫𝐧 𝐜𝐨𝐡𝐨𝐫𝐭 of patients with smoldering #myeloma! Helpful for initial discussion in patients with 𝐇𝐢𝐠𝐡-𝐑𝐢𝐬𝐤 𝐒𝐌𝐌 re. clinical trials vs active surveillance vs Len tinyurl.com/4w4bmzen 1/4

Further discussion on this topic in the #DataMethods forum here: discourse.datamethods.org/t/random-vs-fi… @f2harrell @Lester_Domes

👇Thoroughly enjoyed this outstanding paper @IanMarschner. Perhaps a useful interpretation of Conf(BENEFIT)=0.94 is that the region of θ values corresponding to BENEFIT has 4 or less bits of information against it as per @Lester_Domes & @dailyzad 👉 bmcmedresmethodol.biomedcentral.com/articles/10.11…